GBIO vs. OMER, OVID, ATOS, RENB, RIGL, GALT, MACK, TRVI, LFCR, and GTHX
Should you be buying Generation Bio stock or one of its competitors? The main competitors of Generation Bio include Omeros (OMER), Ovid Therapeutics (OVID), Atossa Therapeutics (ATOS), Renovaro (RENB), Rigel Pharmaceuticals (RIGL), Galectin Therapeutics (GALT), Merrimack Pharmaceuticals (MACK), Trevi Therapeutics (TRVI), Lifecore Biomedical (LFCR), and G1 Therapeutics (GTHX). These companies are all part of the "pharmaceutical preparations" industry.
Omeros (NASDAQ:OMER) and Generation Bio (NASDAQ:GBIO) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, community ranking, institutional ownership, valuation, risk, dividends, profitability, media sentiment and analyst recommendations.
Omeros received 703 more outperform votes than Generation Bio when rated by MarketBeat users. Likewise, 71.80% of users gave Omeros an outperform vote while only 67.86% of users gave Generation Bio an outperform vote.
Omeros has a net margin of 0.00% compared to Omeros' net margin of -1,696.87%. Omeros' return on equity of -73.57% beat Generation Bio's return on equity.
Omeros has higher earnings, but lower revenue than Generation Bio. Omeros is trading at a lower price-to-earnings ratio than Generation Bio, indicating that it is currently the more affordable of the two stocks.
48.8% of Omeros shares are owned by institutional investors. Comparatively, 95.2% of Generation Bio shares are owned by institutional investors. 10.9% of Omeros shares are owned by company insiders. Comparatively, 21.1% of Generation Bio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
In the previous week, Generation Bio had 8 more articles in the media than Omeros. MarketBeat recorded 16 mentions for Generation Bio and 8 mentions for Omeros. Generation Bio's average media sentiment score of 0.27 beat Omeros' score of -0.04 indicating that Omeros is being referred to more favorably in the media.
Generation Bio has a consensus target price of $8.00, indicating a potential upside of 111.08%. Given Omeros' stronger consensus rating and higher probable upside, analysts plainly believe Generation Bio is more favorable than Omeros.
Omeros has a beta of 1.34, meaning that its stock price is 34% more volatile than the S&P 500. Comparatively, Generation Bio has a beta of 2.87, meaning that its stock price is 187% more volatile than the S&P 500.
Summary
Generation Bio beats Omeros on 10 of the 17 factors compared between the two stocks.
Get Generation Bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for GBIO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Generation Bio Competitors List
Related Companies and Tools
